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Abstract
Assessment of human cancer risk from animal carcinogen studies is severely limited by inadequate
experimental data at environmentally relevant exposures, and procedures requiring modeled
extrapolations many orders of magnitude below observable data. We used rainbow trout, an animal
model well suited to ultra low-dose carcinogenesis research, to explore dose-response down to a
targeted 10 excess liver tumors per 10,000 animals (ED001). A total of 40,800 trout were fed 0–225
ppm dibenzo[a,l]pyrene (DBP) for four weeks, sampled for biomarker analyses, and returned to
control diet for nine months prior to gross and histologic examination. Suspect tumors were
confirmed by pathology, and resulting incidences were modeled and compared to the default EPA
LED10 linear extrapolation method. The study provided observed incidence data down to two above-
background liver tumors per 10,000 animals at lowest dose (that is, an un-modeled ED0002
measurement). Among nine statistical models explored, three were determined to fit the liver data
well - linear probit, quadratic logit, and Ryzin-Rai. None of these fitted models is compatible with
the LED10 default assumption, and all fell increasingly below the default extrapolation with
decreasing DBP dose. Low-dose tumor response was also not predictable from hepatic DBP-DNA
adduct biomarkers, which accumulated as a power function of dose (adducts = 100 * DBP1.31). Two-
order extrapolations below the modeled tumor data predicted DBP doses producing one excess cancer
per million individuals (ED10−6) that were 500–1500-fold higher than that predicted by the five-order
LED10 extrapolation. These results are considered specific to the animal model, carcinogen, and
protocol used. They provide the first experimental estimation in any model of the degree of
conservatism that may exist for the EPA default linear assumption for a genotoxic carcinogen.
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Introduction
Assessment of human cancer risk from environmental carcinogen exposures remains a
challenging and inexact prospect. According to the March 29, 2005 Guidelines for Carcinogen
Risk Assessment (www.epa.gov/cancerguidelines), cancer risk is estimated using a human
case-specific dose-response model, if such a model is available (1). In this instance, the
effective exposure leading to a specified level of risk may be interpolated directly from the
dose-response curve. Alternatively, sufficient information on mode of action and critical
parameters may allow development of a biologically-based model to be used in dose-risk
characterization on an agent-specific basis. In the absence of either such model, dose-response
risk evaluations are derived through extrapolation of experimental animal data from a high
dose-response region, which has been measured experimentally, to a low dose-response region
of interest, which has not been measured. The uncertainties introduced by these extrapolations
remains a point of major concern. According to the 1996 Risk Assessment Workshop overview,
“The major problem in cancer risk assessment [will] continue to be the inadequacy of available
[low-dose] data on which to conduct more risk assessments.”
The magnitude of the problem is outlined in Figure 1. Owing to costs and other limitations,
dose-response data from a typical rodent carcinogen bioassay study are generally derived from
a few hundred experimental animals, and thus are statistically limited to observations covering
only about one order of magnitude, between 10% and 100% incidence. The EPA conservative
approach models these high-incidence data to estimate the effective dose of that carcinogen to
achieve 10% incidence (ED10), and to generate a lower confidence limit on this dose estimate
(LED10) as a conservative point of departure for risk extrapolation. If the carcinogen is non-
genotoxic or otherwise expected to produce a non-linear response, a Margin of Exposure
procedure is applied to assign an acceptable human exposure. For genotoxic carcinogens, the
conservative default assumption is that carcinogen-related cancer risk will extrapolate linearly
toward zero exposure, that is, will vary in direct proportion to dose, below the LED10 estimate.
Risk assessments based on this procedure can involve extrapolations several orders of
magnitude below the actual experimental data. For example, estimation of the lifetime dose
leading to one exposure-related (i.e. above-background) cancer case per million individuals
(ED10−6) would require extrapolation to five orders of magnitude below the experimentally
derived LED10 estimate (Figure 1).
Although there have been two previous large-scale rodent studies that might address this need
(2–4), neither study provided treatment-related tumor data below 1% incidence. In any such
low-incidence study, the lower limits for examining carcinogen-related, or background-
corrected tumor risk will be bounded by several factors, among the most important being
background target organ cancer rate. Hence the use of as many as 4080 animals in the BIBRA
study (3) to examine N-nitrosodiethylamine (DEN) dose-response for hepatocarcinogenicity
in Colworth rats provided insufficient statistical power to examine carcinogen-related tumor
response below 5% because that is the approximate background cancer rate for that organ in
that rat strain. The potential for large-scale studies is also severely limited by financial
constraints (animal purchase and husbandry costs, carcinogen cost and availability, pathology
costs) and a need for dedicated infrastructures capable of housing many thousands of
individuals simultaneously.
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We are investigating the feasibility of providing experimental carcinogen dose-tumor response
data extending substantially below the 5% or 1% levels, using a well-established aquatic animal
carcinogenesis model that circumvents many of these limitations. The species used in this
study, the rainbow trout (Oncorhyncus mykiss), has historic background liver and stomach
cancer rates near 0.1% in our facility, can be reared in the tens of thousands at extraordinarily
low per diem and personnel costs, requires an infrastructure far less complex and of modest
size compared to rodent requirements, and has well established pathologies and protocols for
carcinogenesis experimentation (5–7). Based on these attributes, we have designed and
completed the first of two four-part studies to determine if the rainbow trout would be capable
of providing robust cancer dose-response data extending down to or below its historical
background rate of 0.1% in liver.
Much attention also has been given to the possibility that readily quantifiable biomarkers of
cancer risk, such as initial target organ carcinogen-DNA adduction (8–10), might provide
accessible measures of eventual tumor outcome at exposure levels below those that can yield
routinely measurable tumor response, with protocols requiring less time, cost, and
infrastructure than an equivalent tumorigenesis bioassay. An obvious limitation to this
approach, however, is the need for at least some experimental data to validate or assess
biomarker-tumor dose-response correlations, down to measured ultra-low tumor response
levels. We have incorporated one such biomarker assessment, qualitative and quantitative
target organ DBP-DNA adduct measurements, into our study design to explore low-incidence
biomarker correlations. We also assessed the adduction and tumorigenesis properties of several
putative DBP intermediary metabolites, cell proliferation during exposure, and oncogenic Ki-
ras mutational profiles in tumors at the end of the bioassay period to better understand dose-
related mechanisms of tumorigenesis in this model.
DBP was selected as the test compound for this ED001 study due to its potency and widespread
distribution in the environment. DBP is considered to be the most powerful naturally occurring
carcinogen of the polycyclic aromatic hydrocarbon (PAH) class when tested in animal models
of cancer (11,12). It is effective in multiple species (rat, mouse, trout, medaka), elicits tumors
in multiple target organs (mammary gland, skin, liver, lymphoid system, lung in rodents; liver,
stomach, swim-bladder in fish), and produces tumors via several routes of exposure (dietary,
dermal, i.p. injection, transplacental) (11–16). DBP is found in the environment in particulates
formed by combustion of smoky coal (17), in soil and sediment samples (18), and in cigarette
smoke condensate (19). The human cancer risk posed by this potent genotoxic compound
remains to be established.
Experimental Procedures
Materials
Dibenzo[a,l]pyrene (DBP ≥ 98% by HPLC) was obtained from the National Cancer Institute
(NCI) Chemical Carcinogen Reference Standard Repository (Chemsyn Laboratories, Lenexa,
KS, USA). This potent carcinogen was handled and stored in full compliance with Oregon
State University (OSU) and NIH Guidelines for the use of Class C carcinogens. The semi-
purified Oregon Test Diet (OTD) was prepared as described previously (20), except that
menhaden oil (National Marine Fisheries Service, Charleston, SC, USA) was substituted for
salmon oil. DBP was incorporated into the OTD at the stated concentration on a dry ingredients
basis. Every batch of diet was assayed for DBP content, and results published elsewhere (21).
The DBP dihydrodiols and dihydrodiol epoxides used in the embryo microinjection study were
a generous gift of Albecht Seidel (Biochemisches Institute fur Umweltcarcinogene,
Grosshansdorf, Germany).
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Animals and exposure conditions
Shasta strain rainbow trout (Oncorhynchus mykiss) were hatched and reared at the OSU
Sinnhuber Aquatic Research Laboratory (SARL) under previously detailed procedures (6,
20). All animal protocols were in accordance with NIH Guidelines and approved by the OSU
Institutional Animal Care and Use Committee (IACUC). For each of four independent dose-
response experiments, trout fry (initial weight 1.5 grams) were randomly assigned to 102
replicate tanks of 100 individuals each, and fed standardized OTD (20) until commencement
of carcinogen treatment. Trout fry were then fed ODT only, or one of seven levels of DBP
incorporated into OTD, for 4 weeks (Table 1). Each quartile included one sentinel tank of 100
fish in each of the eight exposure groups, to provide for biomarker sampling without disturbing
fish density-growth interactions among tanks used for tumor determination. On days 15 and
29, 50 fish per dose per time point were sampled from these tanks for analysis of cell
proliferation and DNA adducts. Following DBP treatment all remaining fish were fed OTD
for the duration of the study.
Trout at each treatment dose were terminated beginning nine months later, under a gross
necropsy protocol requiring 28 days to complete for each of the four replicate studies. Possible
growth and time effects on tumor outcome were controlled by reduction of feeding to a
minimal-growth maintenance schedule, and use of a random numbers routine assuring an
average date of necropsy on day 15 among the replicate tanks at each carcinogen dose. By this
strategy, there were no significant differences in tumor incidences among groups necropsied
before and after day 15 (data not shown).
Histopathology
At necropsy, trout were deeply anesthetized in tricaine methane sulfonate, weighed, and the
gill arches cut to allow bleeding. The liver, stomach, and swim bladder were removed from
each fish and examined by a pathologist (JDH) with a dissecting microscope to detect gross
tumors. We note that stomach and swim bladder tumors in the trout are readily detectable on
the surface of the organs, and over 95% of liver tumors also appear on the surface. Suspect
tumor locations were marked on livers and notes taken in order to successfully retrieve all
grossly observed tumors. The organs were fixed in Bouin’s solution for up to a week. Livers
were then cut into 1 mm slices in which any interior tumors show up distinctly as pale yellow
spots against the darker mottled background of normal liver tissue. All tumors and questionable
lesions from the control and low dose groups were embedded for histological confirmation,
but sections were not made from every liver in these groups if neither gross nor hand-slicing
observation revealed any lesions. At higher doses, a single slide, having one or more tumors,
was made from each tumor-bearing liver. With this protocol liver tumor incidence was
histologically verified, whereas tumor multiplicity (not reported) above 1.0 might include some
unconfirmed lesions. Sections were routinely stained with hematoxylin and eosin and
established criteria for classification of trout liver tumors (6,22) applied. All pathological
confirmation was by a single pathologist (JMS). Among the total of 1603 liver neoplasms
identified in the study, the majority (71%) were hepatocellular carcinoma, 17% were mixed
hepatocellular/cholangiocellular carcinoma, and 9.5% were hepatocellular adenoma. A few
cholangiocellular carcinomas (1.5%), cholangiocellular adenomas (0.6%), and mixed
adenomas (0.2%) were observed. Although a detailed morphometric study was not carried out,
the observed spectrum of neoplasms was similar to this in all treatment groups and there was
no apparent effect of DBP dose on the spectrum of observed tumor phenotypes. All stomach
and swimbladder neoplasms examined were papillary adenomas. Whereas stomach
adenopapillomas occurred frequently, only a few adenopapillomas were observed in the swim
bladder among the thousands of animals examined. The response was too weak in this target
to be of value in this investigation and is not further discussed.
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DBP-DNA adducts in liver and stomach were examined using 3 pools of 5 samples each, taken
from each sentinel tank of fish at days 15 and 29 of DBP treatment. Because trout liver appears
largely deficient in global excision repair, bulky DNA adducts accumulate linearly with days
of exposure and this time point thus approximates total cumulative DBP-DNA adduction in
the target organ (23). DNA was purified and adducts initially characterized by 33P-HPLC post
labeling as well as 32P-TLC post labeling, as described previously (14,24,25). Total hepatic
DBP-DNA adducts were quantified for each treatment group using the more sensitive 32P-TCL
post-labeling method. Stomach DNA adducts were not quantified for this study.
Statistical Methods
Liver and stomach tumor incidence data were modeled as functions of the full range of DBP
doses with the single exclusion of the highest dose (225 ppm) liver data due to the observed
plateau of the liver tumor incidence as has been previously reported at this dose in the trout
model (25). Standard error (SE) bars for pooled total (uncorrected) incidence (Figure 3B) are
empirical based on observed variation between quartiles. The variation between replicate
quartiles was found to be consistent with binomial variation at each dose modeled with the
single exception of the liver data for DBP dose 28.4 ppm where there was considerable over-
dispersion between replicate quartiles (11.6 times expected). SE bars for observed background-
corrected incidence (Figure 4) are approximate and model-based (asymptotic likelihood-based
assuming binomial variation at each dose for total (uncorrected) incidence with a variance-
inflation factor of 11.6 included for the 28.4 ppm dose in liver tumor data only).
Nine models with independent background (extra risk) were initially fit to the total tumor
incidence data. The Ryzin-Rai model (26) plus eight dichotomous models in the EPA
Benchmark Dose Software (27) (gamma, Gompertz, Weibull, multistage, the two probit-type
and the two logistic-type models) were all fit by maximum likelihood (assuming a conditionally
binomial distribution) using the Nlmixed procedure in SAS version 9.2 (when allowing
overdispersion at dose 28.4 ppm) and the EPA BMDS (27) software. Lack of fit was determined
by likelihood ratio tests versus a saturated model with a parameter for every dose. Most models
fit very poorly and only the three models that fit well are shown in the results. For liver tumor
incidence data a quadratic term added to the logit linear in log dose model greatly improved
the fit (p=0.003 likelihood ratio test for the quadratic term). Well-fitting linear (or quadratic)
logit and probit models are linear (or quadratic) in log of DBP dose. The background incidence
is small for both organs and, therefore, the results and conclusions are essentially the same
whether one assumes independent background (extra risk) or additive background (added risk).
Because the liver incidence pooled across quartiles at dose 28.4 ppm was highly consistent
with the trend observed at neighboring doses, the conclusions regarding model lack of fit for
liver data were the same whether or not the 28.4 ppm data were included in the modeling and,
when it was included, whether or not a random quarter effect was added for the 28.4 ppm dose
data.
LED10 values, using high-dose subsets of the observed liver and stomach data were obtained
from the Probit procedure in SAS (inversecl option) using logit linear in log dose models and
binomial variation (which meant that the over-dispersion of the liver incidence data at the DBP
dose of 28.4 ppm would not be included and, therefore, would not penalize the LED10 approach
by making it even more conservative). Hepatic DBP-DNA adduct accumulation data were log
transformed and then modeled as a linear function of the log of DBP dose using the Reg and
Glm procedures in SAS. The low-incidence log-log slope of the Ryzin-Rai model was
compared to the adduct log-log slope with a Z-test assuming approximate normality and
approximate independence of the two estimates.
Bailey et al. Page 5













Pathways to DBP-DNA adducts in trout
To investigate the metabolic origins of trout DBP-DNA adduction, trout embryos 27 days post-
fertilization were microinjected with 1 µL of DMSO or 1 µL of DMSO containing either DBP
(1, 10, 100, 1000 µg) or one of the following metabolites of DBP (250, 1000 ng): (+)-11,12-
dihydrodiol, (−)-11,12-dihydrodiol, (+)-syn-11,12,dihydrodiol-13,14- epoxide, (−)-anti-11,12
dihydrodiol-13,14- epoxide and (±)-8,9-dihydrodiol. Two hundred embryos were injected per
treatment group, with the injection directed into the yolk. The injected embryos were placed
in incubation trays, hatched and reared to the sac-fry stage according to standard protocols.
Three weeks days after hatching (22 days post-injection) and resorption of the yolk sac, two
batches of 10 livers were taken from the survivors, immediately frozen in liquid nitrogen and
stored at −80°C for adduct analysis. Remaining fish were fed OTD for 11 months, then sampled
for tumors as described previously.
Cell proliferation analysis
Cell proliferation was assessed by proliferating cell nuclear antigen (PCNA)
immunohistochemistry. PCNA was measured in livers and stomachs of 5 fish per dose per
quartile sampled on days 15 and 29. Tissues were fixed for 24 hours in 10% neutral buffered
formalin, then processed through a graded series of ethanols and xylene for embedding in
paraffin. After processing and paraffin embedding, 4–5 µm sections were cut and mounted on
charged slides, deparaffinized, and rehydrated in distilled water. The primary antibody was
mouse anti-PCNA, PC10 (Dako, Carpinteria, CA), an antibody that has been validated for use
in rainbow trout (23). The Dako Envision polymer system conjugated with peroxidase was
used for the secondary antibody, and 3-amino-9-ethylcarbazole (AEC) was used as chromagen.
Slides were counterstained with hematoxylin and mounted with Crystalmount (Biomeda
Corporation, Foster City, CA). For each liver, 500 hepatocytes from each of two sections were
counted (1000 per fish). For stomach, 500 surface epithelial cells and 500 glandular epithelial
cells were counted per section (1000 of each cell-type per fish).
Detection of oncogenic Ki-ras
After digestion of tumor tissue with proteinase K, mutations in Ki-ras were analyzed by 3’-
primer mismatch polymerase chain reaction (PCR) as described previously (28). Negative
control DNA from livers of untreated animals gave PCR products only with the normal primers
under these conditions. Positive mutations were verified by direct sequencing.
Results
Tumor dose-response data
The study design (see Table 1) used a protocol incorporating DBP into the standard OTD (5),
to elicit tumors in trout liver and stomach. Two preliminary studies of 2000 animals each were
conducted over a two-year period in order to select informative doses for the large-scaled
experiment, and to permit model statistical calculations for optimal distribution of individuals
along the dose range. A 30-year historic data base with the Shasta trout strain in our facility
indicated a background liver cancer rate of approximately 0.1%, or 10 tumor-bearing animals
per 10,000 individuals. Our aim in the final design was to elicit double this background
incidence in liver at the lowest exposure dose (10 additional tumor-bearing animals per 10,000
trout) if the response remained approximately logit linear in log dose, as modeled for the higher
dose pilot data, or a lesser number if it did not. The design called for 10,000 control animals
(0 ppm DBP) distributed as 25 replicate tanks of 100 animals each for each quartile in the
study, in order to provide a measure of true background and its variance. An additional 10,000
trout were similarly committed to estimate tumor response and variance at the lowest DBP
exposure dose of 0.45 ppm. A further 18,000 animals were apportioned in decreasing number
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with increasing dose and anticipated tumor response (Table 1). Dietary DBP doses covered a
500-fold exposure range, and were projected to provide liver tumor incidence data ranging
from near background up to approximately 70% at the highest dose.
Of the initial 40,800 trout committed to the study design, 3200 were removed for early
biomarker determinations and 32,316 were eventually sacrificed and the data utilized for tumor
dose-response assessment (Table 1). Mean tank survival among these animal tanks was 92.4%,
and deaths were unrelated to DBP dose. The remaining animals were lost from the study due
to isolated malfunctions that disqualified 23 tanks from being considered. The protocol utilized
a four-week carcinogen exposure period, after which animals were reared on control diet
without DBP exposure for an additional nine months prior to sacrifice for histopathological
examination. Logistics required that the study be carried out as four independent replicate
experiments, each using one fourth of the animal total.
The observed total liver tumor incidences (background plus carcinogen-driven) for each of the
four replicates are depicted in un-modeled, linear coordinates in Figure 2 (2A, entire incidence
range; 2B, low incident range expanded). It is evident, especially in Figure 2A, that linear scales
compress data in the most pertinent low dose region, and permit only a few general conclusions.
The liver data set displayed a generally sigmoidal dose-response curve from above 60% to near
zero, with independent replicates at each dose point falling within an absolute incidence range
of 0.14 or less for the liver data (Table 1; Figure 2B). The measured pooled (mean) incidences
were greater than control at all DBP doses, but not significantly so at either of the two lowest
DBP doses, 0.45 and 1.27 ppm (Table 1). For six of the seven doses modeled (see below), the
data are consistent with binomial variation between replicates (overall test for over-dispersion
p = 0.45). The exception is the 28.4 ppm dose, where there is strong evidence of over-dispersion
(deviance/df = 11.6, p<0.0001). Examining the pooled data (Fig 2B, solid line) at low range,
as dose decreased the pooled line appeared curvilinear rather than straight as it approached
background. Even without modeling, the observed extent of convex or “sublinear” behavior
suggests that a low-incidence direct proportionality model would not fit the trout liver data,
irrespective of background correction
Figure 2C shows the total tumor incidences in stomach for each of the four quartiles, also on
linear coordinates. The four quartiles provided reproducible results, with the variation
consistent with binomial variation at every dose (overall test for over-dispersion p = 0.18).
DBP produced a less potent dose-response in stomach than in liver and did not approach the
plateau observed at highest DBP dose in liver. The measured pooled incidences were greater
than control at all DBP doses, but not significantly so at the three lowest doses of DBP (0.45,
1.27, 3.57 ppm). The background incidence in stomach was approximately 1.5 times that in
liver (Table 1)
Although Figure 2 provides a useful overview of the focus and range of incidences observed
in the two organs, it is clear from the data compression inherent in the linear-linear plot that a
different scaling is necessary to more appropriately visualize low-dose, exposure-related tumor
response at ultra-low incidence. Many scales are available. Waddell (29), for instance, recently
reinterpreted the mouse 2-acetylaminofluorene (2-AAF) ED01 data using a scale linear in
response (tumor incidence) but logarithmic in dosage (log 2-AAF molecules/kg/day). This
scaling was, however, challenged on the basis of asymmetric data compression artifact (30).
By comparison, a simple log-log plot of the trout data set (Figure 3) avoids data compression
at low doses and provides a sensitive scaling for examining the EPA conservative default
assumption that exposure-related response will vary in direct proportion to carcinogen
exposure dose, without any ad hoc assumptions such as those inherent in semi-log scaling. On
a log-log plot of background-corrected incidence vs. dose, low-incidence data consistent with
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direct proportionality will appear as a straight line with slope not significantly different from
1.0, while a slope clearly greater than 1.0 will instead indicate sublinear behavior.
Model fitting to the tumor dose-response data
Figure 3A depicts the liver and stomach tumor incidence data sets without correction for
observed background, which were 0.12% (95% binomial CI 0.056–0.21%) for liver and 0.18%
(95% binomial CI 0.10–0.30%) for stomach. Figure 3B illustrates exposure-related
(background-corrected) incidence vs. dose on the log-log. Though the variation in estimates
of tumor incidences at the lower doses appear large on a log-log scale (e.g. Figure 2B, Figure
3A, 3B, Figure 4A), it must be noted that these in fact represent experimentally estimated
frequencies of such very rare events as 1–2 tumors per 2000 individuals (Table 1). This is why
four repeats, each consisting of as many as 25 replicates of 100 animals each were required to
reasonably estimate response and its variance at low or zero dose. We note that low precision
in estimating true background rate contributes strongly to the wide SE intervals for corrected
incidences at the two lowest carcinogen doses and to the fact that the lower SE boundary
includes zero for the corrected response in liver at the lowest dose (Figure 4A). Precision for
background estimates has decreasing contribution to the SE intervals with increasing dose and
observed incidence. These results illustrate that background tumor incidence in the model of
choice is perhaps the limiting statistical factor in the design and interpretation of ultra-low
dose-response studies.
The carcinogen-related (background corrected) tumor responses in liver and stomach are
depicted in Figure 3B. The precise relationships between these responses and the LED10 default
response were established by fitting models incorporating both background and dose response
to the incidence data in Table 1 (see Statistical Methods). Figure 4A depicts the dose-response
part of three well-fitting models, as well as an LED10 extrapolation derived solely from the
higher dose/response region of the liver data set. We do not attach a priori any special biological
significance to any of the three mathematical functions, but simply use them to explore the
degree to which the experimentally measured tumor incidence data are compatible with the
EPA default linear extrapolation. As seen in Figure 4, the three dose-response models (Ryzin-
Rai, logit quadratic and probit linear) all fit the data extremely well (p > 0.8 for each lack of
fit test respectively with 3, 3 and 4 df). In the well-fitting Ryzin-Rai model, there is a slope
parameter that describes low-dose behavior. If that parameter is not clearly different from 1.0,
then the estimated low-dose behavior is consistent with the EPA low-dose direct
proportionality model. In fact, however, the Ryzin-Rai slope parameter is estimated as 2.278,
with an asymptotic standard error of 0.356, demonstrating substantial sublinearity and strong
evidence against direct proportionality at low dose (p<0.0001, likelihood ratio test that
parameter = 1.0). The fitted logistic quadratic and linear probit models lack single slope
parameters describing low-dose behavior, but instead show slopes that are even steeper than
that for Ryzin-Rai, increasingly so with decreasing DBP dose (Figure 4A) Therefore, we can
conclude that none of the three models that do fit the liver data well is compatible with the
EPA default model, which would require that tumor response remain in direct proportion to
carcinogen dose at low incidence.
A 5-log-order extrapolation of the default curve, using the LED10 estimate from the higher
carcinogen doses only, estimates the dose expected to provide one excess cancer in a million
individuals (ED10−6) to be 0.126 ppb DBP (Table 2). By comparison, the models fitted to the
complete low-dose data set require only a two-order extrapolation to provide ED10−6 estimates.
These virtually safe dose estimates for liver range from 66 ppb (Ryzin-Rai) to 186 ppb (linear
probit) DBP, doses that are 500–1500-fold greater (less hazardous) than predicted by the linear
default procedure (Table 2).
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We also explored fitting and extrapolation of the stomach tumor data set. An interesting
possibility is that the attenuated response with decreasing dose in stomach reflects a hormetic,
or J-shaped, dose-response in this organ (31). However, the suggestion of a J-shaped response
curve rests solely on the single data point at lowest DBP dose, which is in fact statistically
indistinguishable (P < 0.5) from the responses at zero and 1.27 ppm. The four models that were
successfully explored were the LED10 linear extrapolation, Ryzin-Rai, linear probit, and linear
logit (Figure 4B). In stomach there was greater variation at the four lowest DBP doses in both
the data replicates and the fits of three models, compared with liver. These differences in target
organ response assessments occur in large part because our choice of animal distributions for
the study was optimized for liver, which had only two thirds the background incidence and a
less steep DBP response compared with stomach. This is analogous to the less informative
outcome that might result were an ED001 study undertaken without adequate preliminary dose-
response data for the major (or only) target organ. As a consequence, model fits for the stomach
data are determined chiefly by the high-dose data because the low-dose data are imprecise.
Despite these limitations, we were able to conclude that the stomach data, like liver, are not
compatible with the EPA default assumption. The logit linear in log dose model (3 parameters)
fits the data well (p = 0.336, 5 df lack of fit test), as does a 3-parameter probit in log dose model
(p = 0.535, 5df lack of fit test) and a 4-parameter Ryzin-Rai model (p = 0.541, 4 df lack of fit
test). The slope estimates at low-dose for both the logistic linear model (1.97, SE 0.071) and
Ryzin-Rai models (2.743, SE 0.454) are well above 1.0 indicating substantial sublinearity and
strong evidence against direct proportionality (p<0.0001 likelihood ratio test that
parameter=1.0). The slopes of the fitted curves were also extrapolated to estimate conservatism
of the linear default model for this organ. These virtually safe dose estimates (linear logit, 0.12
ppm; Ryzin-Rai, 0.46 ppm; linear probit, 1.81 ppm) cover a greater range than for liver owing
to the greater dispersion in the low-dose stomach data, and are 360 – 5500 times greater than
the conservative LED10 10−6 estimate of 0.00033 ppm DBP for cancer risk in stomach.
Biomarker results
Initial studies were conducted to resolve and quantify individual DBP-DNA adducts in the
trout model, and to explore their metabolic origins (Figure 5–Figure 7.) HPLC resolution
of 33P-HPLC postlabeled adducts revealed three major adducts in stomach (Figure 5B), that
partially overlapped with those generated by DBP metabolism in human MCF-7 cells (not
shown). The major liver adducts were more numerous and much more polar than those in
stomach (Figure 5A).
To explore metabolic origins, DBP and several potential metabolic intermediates (Figure 6)
were microinjected into trout embryos at total doses up to 1000 ng/embryo, for determination
of DNA adduct profiles and gross tumorigenicity. By this protocol, DBP elicited primarily
liver-type adducts in total embryo DNA (Figure 7, upper panel), and a potent dose-response
for hepatic tumor induction nine months later (Figure 7, lower panel). The synthetic (−)-11,12-
dihydrodiol DBP derivative showed adduction and tumorgenicity similar to parent DBP. The
(−)-anti-11,12-dihydrodiol-13,14-epoxide elicited primarily stomach-type DNA adducts, and
a strong liver tumor response nine months later in liver. Interestingly, no stomach tumors were
elicited by this DBP intermediate, which suggests that elements other than DBP adduct
phenotype determine tumor organospecificity in this model. The (+)-syn-11,12-
dihydrodiol-13,14-expoide showed similar but less extensive stomach-type adduction and liver
tumor initiation. The DBP-(+/−)-7,8-dihydrodiol derivative induced no detectable adduction
or tumorigenicity. We note that this experiment was not designed with sufficient replicates to
establish an absolute carcinogenic potential of each DBP derivative by embryo microinjection.
Further interpretation is also limited by the unusually high background liver cancer rate in this
particular study.
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Following these characterizations, total genomic DBP-DNA adducts were examined as
potential biomarkers that might explain, or be used to predict, the shape of the tumor dose-
response curve seen in trout liver. Figure 8A compares the un-modeled liver adduct and tumor
incidence data sets at low DBP dose. This comparison suggests that use of adduct data as a
surrogate for tumor data would be misleading here because the adduct data curve is less steep.
This visual impression is born out by modeling results. As seen in Figure 8B, the adduct data
set can be modeled successfully on a log-log plot as a straight line (p=0.47 lack of fit test) with
a slope of 1.31 (SE 0.07). Although this indicates a significant (p<0.0001) sublinearity in adduct
dose-response, it is a small degree of sublinearity compared to that observed in the modeling
of the exposure-caused liver tumors. The Ryzin-Rai model gave a low-incidence slope of 2.28
(SE 0.036) on a log-log plot, a slope that is significantly greater than the 1.31 observed in the
adduct model (p=0.007 two-sided approximate Z-test). Further, the other two well-fitting
models indicate even steeper slopes (and therefore greater sublinearity) than that in the Ryzin-
Rai model (Figure 4A). Therefore, use of liver DBP-DNA adducts as biomarkers to predict
low-dose tumor response would have been misleading in this study. Specifically, adduct
measurements, by being considerably less sublinear, would have suggested that the
conservativeness of the LED10 extrapolation was much less than suggested by the actual tumor
modeling (Fig. 4A).
It was important to know if non-concordance between adduct and tumor dose-response might
be ascribed to dose-dependent changes in DBP metabolism that might alter the types, and hence
the possible tumorigenic potencies, of DBP-DNA adducts formed. This was explored by
examining the 33P-HPLC profile of hepatic DBP-DNA adducts for dose-dependent changes.
As expected, the absolute level of each HPLC adduct peak in liver was seen to increase with
DBP dose (Figure 5C), however the ratio among adduct peaks did not appear to change with
DBP dose. Hence non-concordance between adduct and tumor dose-responses are not due to
dose-dependent alterations in the types of adducts formed by DBP.
We also investigated the effect of DBP dose on the proportion of proliferating cells in livers
and stomachs of fish sampled at day 29, the end of carcinogen treatment. There was no evidence
for an effect of DBP on PCNA staining among hepatocytes, stomach surface cells, and stomach
glandular cells, except for a slight diminishment in liver at highest DBP dose (Figure 9).
Therefore, while reduced proliferation might contribute to the plateau in hepatic tumor
response at high DBP exposures, there is no evidence that this contributes to the diminishing
response at low DBP levels. We did not explore markers of proliferation other than PCNA, or
the potential role of dose-dependent apoptosis in this study.
Discussion
Data extrapolation, non-linearity, and risk characterization
The LED10 default model has, up until now, required extrapolation of measured animal data
downwards through five orders of magnitude (100,000-fold below the modeled data set) to
estimate the dose producing one excess cancer case in a million animals. The current dataset,
however, extends down to an observed 0.02% liver tumor incidence and thus limits the need
for extrapolation to less than three orders of magnitude beyond the lowest data point.
Extrapolation through this greatly reduced range (200-fold below the modeled data set) by
three different well-fitting models provides estimates of the virtual safe dose for liver that are
500 to 1500 times higher than that provided by the conservative LED10 extrapolation (Table
2). Similar results were obtained by modeling of the stomach tumor data. These findings in
two different target organs provide the first case-specific experimental measures of the degree
of conservatism that might exist for the default linear extrapolation method. A similar ED001
experiment is presently under way with aflatoxin B1, the most potent known human dietary
carcinogen, to expand our knowledge of carcinogen specificity in ultra-low dose-response.
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DNA adducts as biomarkers of tumor dose-response
The present study examined two commonly considered biomarkers of effective carcinogen
treatment, genomic DBP-DNA adducts accumulated during exposure, as well as Ki-ras
oncogenic mutational profiles in tumors nine months after DBP treatment. Despite great
progress in establishing relationships between carcinogen exposures, target organ carcinogen-
DNA adducts, and tumor outcome, previous efforts have been unable to couple tumor with
adduct data at ultra-low exposures and incidences. As a consequence, data have not been
previously available to directly test the utility of DNA adducts as predictive biomarkers of
tumor response at ultra-low incidence. We have shown here that the shapes of the initial
carcinogen-DNA adduct dose- response and the eventual hepatic tumor response to carcinogen
treatment can be distinctly different. Total genomic DBP-DNA adducts increased not linearly
but as a power function of DBP dose, and thus modeled as a straight line with slope 1.31 (SE
0.061; 95% CI 1.19, 1.44) on a log-log scale. This DBP dose-adduct response behavior was
significantly different from the DBP dose-tumor incidence response in liver. Two of the three
models fitting the liver tumor data well, quadratic logit and linear probit, display increasingly
steep slopes, and thus increasing departure from the DBP-DNA adduct line, with decreasing
carcinogen dose. For these two models, there is no circumstance under which DBP-DNA
adduction could be used to accurately predict tumor response at low exposure, or a virtually
safe DBP dose. The third model, Ryzin-Rai, does approach linearity over the low dose-
incidence range on the log-log scale (Figure 4A); however, the slope in this region is 2.28, not
1.31 (p<0.007). For this model as well, there is compelling evidence that measurements of
genomic DBP-DNA adducts do not provide an accurate biomarker for ultra-low dose cancer
risk evaluation.
The effect of these differences on risk evaluation are considerable. Figure 8A compares the
shapes of the un-modeled adduct and incidence dose-response curves, normalized at the 10.1
ppm DBP dose point. If we use the fitted adduct function log(adducts) = 2.000 + 1.31 log
(DBP) to predict the shape of a theoretical tumor dose-response curve below this 10.1 ppm
DBP data point, as might be done in the absence of lower-dose tumor data, we obtain by
extrapolation an ED10−6 estimate of 2.5 ppb DBP. This estimate is 20-fold greater than that
provided by the LED10 assumption, and thus leads to the conclusion that the LED10 assumption
is conservative by a factor of 20 in this case. By comparison, ED10−6 estimates obtained by
extrapolation of the models fitted to the entire liver tumor data set were 500–1500 fold larger
(less conservative) than the LED10-derived ED10−6 estimate (Table 2). Therefore, use of the
adduct data in place of the more sublinear tumor data would lead to a 25- to 75-fold error in
estimation of a virtually safe DBP dose, and a comparable difference in the assessment of
LED10 conservatism, for this case-specific model.
Discordance between DNA adduction and tumor responses have been recognized for some
time now with other carcinogens and animal models. For example, Poirier and Beland (32)
found a non-correlation in BALB/C mice treated with 2-acetylaminofluorene between steady-
state levels of DNA alkylation in bladder, which appeared to be linear, and bladder tumor
incidence at 24 months, which was notably sub-linear. Driver et al. (33) reported a similar
discordance between dimethynitrosamine-induced DNA adducts, which were depicted as a
straight line plot on linear coordinates, and mesenchymal tumors, which showed a distinct
sigmoidal dose-response on similar coordinates. In both studies, however, adduct-incidence
correlations were restricted to the higher dose-response region (observed incidences above
0.3% or 1.25%, respectively) and not usable for ultra-low dose-response correlations. The latter
study also suffered from absence of statistical treatments to support the claims.
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Mutations as biomarkers of low-dose risk
A recent suggestion to incorporate more science into the risk assessment process involves
developing high quality mutation dose response data in reporter genes that define the low dose
mutagenic potential (8), followed by application of a reasonable safety factor to cover
individual differences in metabolism and repair. Although carcinogen-driven DNA adducts
provide important information on molecular dose at target tissues, cancer is considered to be
a disease of mutations. DNA adducts are not mutations, and can induce mutations only with
appropriate cell survival, adduct processing and fixation by replication. Perhaps under certain
restricted conditions, cumulative carcinogen-DNA adducts might serve as predictive
biomarkers of carcinogen-related (background-corrected) tumor response at ultra-low
exposure, for instance where total adducts accumulate linearly with dose, the spectrum and the
genomic distribution of adducts are independent of dose, adduct-driven oncogenic mutations
remain in direct proportion to dose, and cellular homeostasis is independent of dose. This set
of conditions appears not to be met in the present study.
Dose-dependent induction of CYP bioactivation, and/or saturation of limited DBP-DNA
adduct repair capacity, are plausible mechanisms to explain the exponential dose-response
behavior for genomic DBP-DNA adduction in trout, but can not account for lack of
concordance between adduction and tumor induction. Alternative explanations might include
non-linear dose-responses for adduction, repair, and/or mutagenesis at genes critical to tumor
initiation, rather than genomic DNA. For instance, DBP adduct mutagenic potency may fall
off with decreasing dose and adduct concentration, such that the low number of adducts present
at ultra-low DBP doses might not drive oncogenic mutations above those from endogenous
damage. We have at least partially explored this hypothesis by examining the frequency and
spectrum of oncogenic Ki-ras mutations in liver and stomach tumors. Limitations of the
approach include restrictions in the types and locations of oncogenic Ki-ras mutations
recoverable from tumors, and in our study, a paucity of spontaneous and low-dose tumor
fragments for examination (pathology took precedence, and Buoin’s fixative precluded
mutation examination in fixed tumor specimens). Despite these limitations, there is clear
evidence from stomach tumors that DBP-driven mutations in the Ki-ras oncogene were present
even at low dose. As seen in Table 3, the frequency distribution of oncogenic mutations in
stomach tumors at the two lowest DBP doses (six of six codon 61 adenine based mutations)
appeared to differ from those in tumors from the untreated control fish (three codon 12/13
guanine-based mutations, one codon 61 guanine-based mutation), and the differences became
substantial at higher doses where the contribution of spontaneous tumors would be negligible
(38 of 39 codon 61 adenine-based mutations). The probability that the spectrum of mutations
in stomach tumors in controls and in tumors from the two lowest DBP doses should differ by
chance alone, i.e. are not DBP based, is small (p = 0.033, Fisher’s Exact Test). This result
supports the idea that DBP-DNA adducts are contributing functioning, selectable mutations in
genes critical for tumor development in this model, at least in one target organ, even at lowest
DBP doses. It is intriguing that apparent DBP-driven mutations are detected even in the low-
dose range where total tumor incidences in treated and control groups did not differ
significantly. This may suggest that carcinogen treatment itself elicits an environment in which
cells acquiring carcinogen-driven oncogenic mutations are selected over those carrying
spontaneous mutations in the same oncogene. For liver, only three mutant alleles were detected
among the five control tumors available for examination, and there was insufficient information
to determine if a dose-related shift in mutant allele frequency may have occurred.
Protocol considerations
The current protocol assessed tumor response in a lower vertebrate tumor model. Non-
mammalian status would present an obvious limitation if the present results, which provide an
ED10−6 risk evaluation for DBP in trout, were extrapolated directly to humans, or even to
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rodents. We have suggested no such extrapolation. The goal instead was to provide an expanded
experimental data set down to ultra-low exposures and incidences, to use these data for
assessment of dose-linearity for tumor response, and to assess the utility of DNA adducts as
biomarkers of tumor response at low dose. The results show clearly that the default
extrapolation method for low exposure risk evaluation does not apply for this model,
carcinogen, and protocol, and that adducts were not useful biomarkers for predicting eventual
tumor outcome. While DBP carcinogenic potency may well differ in trout and humans, we
have no basis to conclude that the fundamental shape of the DBP dose-tumor response curve
would differ in these species.
It is also pertinent to consider the extent to which the deficiency in global repair of bulky DNA
adducts seen in the trout model (23) relates to the observed shape of the tumor dose-response
curve. One plausible expectation is that models with significantly decreased DNA repair
capacity might have a greater tendency toward low-dose linearity than those with greater repair
capacity, because they are less capable of adduct removal and mutation avoidance at ultra-low
exposures. The fact that the current findings are not consistent with this expectation makes a
low-dose-linearity response even less tenable than if the model had substantial DNA repair –
that is, an animal with greater repair capacity would be expected to show an even steeper
departure from linearity in the low-exposure region, not less. In this regard the trout provides
a conservative measure of the conservatism in the LED10 default assumption.
A final consideration is that the present study relates most directly to risk characterization for
juvenile cancer, which is second only to accidents as the leading cause of death among children
in the US. The focus on juvenile risk is a direct consequence of our less-than-lifetime exposure
protocol, which was necessitated by restrictions of the model (long life span, continued growth)
as well as insufficiency of pure DB(a,l)P anywhere in the world to permit lifetime exposure in
trout or any other vertebrate model. While juvenile cancer risk assessment is undeniably
important, it is also pertinent to consider how data gathered from partial life exposure protocols
may relate to the more traditional lifetime risk assessments. Based on our historical data, we
would expect tumor incidence at any DBP dose to increase with time of treatment and time for
tumor growth in the trout model. As a consequence, ED10−6 estimates from this model would
be expected to increase with longer treatment or grow-out times. The more important question,
however, is whether the fundamental shape of the dose-response (e.g. linear vs. non-linear)
would be influenced by either parameter in trout, or any other vertebrate model. If so, then the
use of data from life-time exposure/grow-out protocol to assess juvenile cancer risk may
provide misleading results, and the reverse would also be true. It is possible, for instance, that
the lack of proportionality in tumor response seen at ultra-low DBP dose in this study might
reflect a time-dose interaction, in which tumors elicited at low dose grow more slowly than
those at high dose. Under this circumstance, non-linearity in dose-response would be an
inherent function of our juvenile termination protocol, and as such would be observed for all
carcinogens eliciting hepatocellular carcinomas in this model. The most direct data we have
on this question derives from our current ED001 study with aflatoxin B1, using a treatment and
grow-out protocol identical to that used for DBP. Two of the four independent trials are now
completed, and the initial results (34) indicate that AFB1 at low dose elicits a dose-response
function that is considerably less steep on a log-log scale than observed in DBP, but still greater
than 1.0. If these initial results are confirmed at the end of the study, the degree of sublinearity
in tumor response at ultra-low dose in the trout model is determined by the carcinogen, and
not the protocol.
Threshold tumor responses
The data presented here demonstrate that hepatic tumor response was not in direct proportion
to DBP dose, but fell increasingly below direct proportionality (slope 1.0 on log/log scale) with
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decreasing DBP dose. The shapes of two of the fitted curves for liver (quadratic logit, linear
probit) and one of the fitted curves for stomach (linear probit) display increasingly steep slopes
with decreasing dose, and thus may be taken to suggest that a finite dose may be reached in
which there would be no observable increase above background tumor rate (slope of infinity),
that is, a threshold. Although these data are consistent with a threshold interpretation, even the
use of over 30,000 animals did not provide proof that a threshold was reached, or would exist,
in either target organ for this carcinogen in this model. Several recent studies have explored
the existence of a threshold for carcinogenicity by genotoxic carcinogens (29,30,35–37).
Fukushima et al. (35) examined the induction of DNA adducts, 8-OHdG damage, and aberrant
crypt foci biomarkers in the colon of rats treated with 2-amino-1-methyl-6-imidazo[4,5-b]
pyridine (PhIP). The study covered an exceptionally wide range of PhIP exposure, 0.001 to
400 ppm fed for 16 weeks, at which time ACF/colon were determined. Rats per treatment
ranged from 61 to 244, and observed ACF/colon ranged from 0.3 +/− 0.7 in controls to 5.0 +/
− 2.8 at highest dose. By graphical analysis on a semilog scale (log dose vs total ACF) the
authors claim evidence for a threshold dose of PhIP of 50 ppm because doses below that did
not produce ACF/Foci different from background by simple pair-wise Dunnet-test. However,
with variances in biomarker response of this magnitude even 250 animals/group provides
insufficient statistical power to assess carcinogen-related response down to a background level
of 0.3 ACF/colon, and especially to demonstrate significant departure from linearity in the low
dose-response range. (The present study, by comparison, required approximately 27,000
animals treated with zero, 0.45 ppm, or 1.27 ppm DBP for adequate statistical power to
demonstrate departure from linearity). In particular, the inability of a Dunnet-test to
differentiate between 0.3 +/−0.7 ACF/colon (n=240) at zero dose, and 0.4 +/−0.8 ACF/colon
(n=212) at 10 ppm does not provide statistical proof that a threshold has been reached or even
that the response is significantly non-linear -- with sufficiently few animals and sufficiently
large variances and background, any dose-response study will arrive at an exposure dose that
does not elicit a response differing significantly from control. In addition, the semi-logarithmic
graphical analysis used by these authors and others (29) is biased toward appearance of a
threshold owing to simple mathematical reasons (expanded dose scale and compressed
incidence scale). The insensitivity of this scaling for differentiating zero and near-zero
incidences at low dose means that even a true proportional dose-response data set, that fits a
straight-line-through-the-origin model, will show an apparent threshold on a semi-log scale.
Fukushima et al. (36) reported no-observed-effect levels for induction of the glutathione-S-
transferase placental form altered foci biomarker in rat liver by low doses of N-
nitrosodiethylamine or 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. In this case as well,
absence of background correction, variability in response, and limitation in animal numbers
mitigate against a robust test of low-dose linearity for either carcinogen. In addition, this model
as well as that reported by Williams et al. (37) used a protocol in which carcinogen treatment
was followed by extended promotion by phenobarbital. At present, risk assessment models for
carcinogenesis consider response to a single agent alone and the influence of a non-genotoxic
promoter on the linearity of carcinogen response was not investigated in these studies. Such
two-factor exposure protocols will require more intensive dose-dose-response study if we are
to understand the interactions of carcinogen and promoter dose on biomarker or tumor response
at low exposures and incidences pertinent to human cancer risk assessment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Hypothetical illustration of the magnitude of extrapolation necessary to evaluate acceptable
human exposure based on typical rodent bioassay data, and the design goal of the present
studies to extend the range of available tumor data. Typical rodent bioassay data range from
approximately 10% incidence upward towards 100%, whereas the ED001 experiments in this
report were designed to seek tumor data down at least two additional orders of magnitude, to
0.1% incidence.
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Incidence of liver and stomach neoplasia versus carcinogen dose. (A) Liver tumor incidence
with each quartile shown separately. Each data point represents mean incidence among
replicates at that dose, and each line represents one of four independent dose-response
experiments. (B) Overall trend in liver tumor incidence for the 5 lowest doses (simple mean
and standard deviation for the 4 quartiles). (C) Stomach tumor incidence with each quartile
shown separately as in A.
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Incidence of liver and stomach neoplasia versus carcinogen dose plotted on a log scale with
four quartiles combined (A) without background correction and (B) corrected for the combined
background incidence. Error bars are standard error (SE) (see Statistical Methods) and the
number of animals per treatment group is shown above the symbols in 3A.
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Extrapolations of the dose-response portion from well-fitting models for trout tumor incidence
data and from LED10 lines. The dotted lines represent default linear extrapolations from
LED10 points of departure, which were established using a standard linear logit model fit to
the incidences from the highest three doses (after excluding the highest dose, 225, for liver).
Points (Xs) are observed pooled incidences corrected for the pooled observed background with
approximate SE bars for the corrected incidences (see Statistical Methods). (A) Three models
that fit the liver data well are quadratic logit (3 dose-response parameters, dashed line), Ryzin-
Rai (3 dose-response parameters, alternating dotted and dashed line) and the linear probit (2
dose-response parameters, solid line). (B) Three models that fit the stomach data well are the
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linear logit (2 dose-response parameters), linear probit (2 dose-response parameters) and the
Ryzin-Rai (3 dose-response parameters).
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DBP-DNA adducts from rainbow trout after 33P-postlabeling/HPLC analysis. Trout were
sampled on day 29 after 28 days of dietary DBP treatment. Each sample represents 3 pools of
5 livers or stomachs. A. Representative liver DNA adduct profile. B. Representative stomach
DNA adduct profile. C. Dose-response of seven major hepatic DNA adduct peaks.
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Structures of DBP and potential intermediate metabolites.
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Effects of DBP metabolites on DNA adduct profiles and comparative carcinogenic potency.
(A) Comparison of hepatic DBP-DNA adducts generated by microinjection of DBP and
metabolites into trout embryos. (B) Comparison of hepatic tumorigenicity of DBP and
metabolites by trout embryo microinjection.
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Dose-response for total DBP-DNA adduction in trout liver. (A) A comparison of the observed
(unmodeled) dose responses for DBP-DNA adduct accumulation and liver tumor incidence at
low DBP exposures. The adduct and incidence data were approximately normalized to the 10.1
ppm DBP dose point by multiplying the observed incidences by a factor of 400. (B) Dose-
response for DNA adduct accumulation at all DBP doses, modeled on the log-log scale. Total
genomic DNA was purified from pooled livers each, taken on day 29 after 28 days of DBP
treatment. Sample size per DBP dose are N=4 pools of five livers each except at the two lowest
doses (N=2 and 3 at DBP dose = 0.45 and 1.27 ppm). Data points represent means +/− SE,
with total adducts quantified by 32P-TLC postlabeling.
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Cell proliferation in (A) hepatocytes, (B) stomach surface cells, and (C) stomach glandular
cells versus carcinogen dose. Five fish per dose per quartile (liver, all 4 quartiles: stomach,
quartiles 3 and 4) were sampled for cell proliferation 2 (not shown) and 4 weeks following
treatment with DBP. A minimum of 1000 cells were counted from each tissue per fish to obtain
the proportion of positively stained cells. Each datapoint represents the mean of 5 fish.
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Extrapolated doses to cause one excess tumor in a million individuals according to selected models.
Extrapolation Type Extrapolated dose (ppb) causing
0.0001 percent incidence1
Ratio (Model over LED10)
Liver Stomach Liver Stomach
Example of an LED10 0.1262 0.3263
Example of an ED10 0.1552 0.3873 1.23 1.19
Probit linear in log dose 186 1813 1480 5560
Logit type model 1584 1205 1250 364
Ryzin-Rai model 66 460 524 1390
1
0.0001 percent incidence = 0.000001 (proportion) incidence = 1 in one million
2
Example based on data for DBP doses 28.4 and 80 (observed incidence greater than 10%) using logit linear in log dose model. The LED10 was calculated
using binomial error (because accounting for overdispersion at DBP dose 28.4 would have shrunk, and therefore penalized, the LED10).
3
Example based on data for DBP doses 80 and 225 (observed incidence greater than 10%) using logit linear in log dose model with binomial error.
4
Logit quadratic in log dose because linear gave poor fit (see results).
5
Logit linear in log dose.
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